James Patterson, MD, PhD
Co-Founder & Head of Discovery Research

James has 10 years’ experience in developing novel synthetic biology technologies, and invented Xap’s foundational IP. Prior to starting Xap, James founded Auxolytic, where he invented and commercialised a novel nutrient dependent safety switch for cell therapies. Auxolytic's foundational technology was published in Nature Biotechnology.

James studied medicine and biochemistry at the University of Cambridge and University College London. He received his PhD in computational and cell biology at the Francis Crick Institute, with Sir Paul Nurse. His PhD resulted in six publications, and was supported by a prestigious Boehringer Ingelheim Fonds Fellowship.